The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3→Lys) and its binding to low density lipoprotein receptors
Abstract
Apo E5(Glu3----Lys) is a naturally occurring apolipoprotein E (apo E) mutant found in patients with hyperlipoproteinemia and atherosclerosis. It has been shown to have a high affinity for low density lipoprotein (LDL) receptors. In this study, mutant apo E5 was produced by Chinese hamster ovary cells by means of an in vitro site-directed mutagenesis technique, and its LDL receptor binding activity was assessed. The apo E5 obtained from gene expression bound more readily to the LDL receptor than did plasma apo E3. The concentrations required for 50% competitive binding of 125I-labeled LDL to the LDL receptors were 58.9 ng/ml for plasma apo E3 and 25.7 ng/ml for the expressed apo E5. The expressed apo E5 displayed 229% normal binding. This result is highly consistent with that obtained with plasma apo E5, which showed 217% normal binding. Although the experimental apo E isoproteins contained more sialic acid than plasma apo E, the extent of sialylation had no effect on the receptor binding of apo E.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies have reported that apoE5 (Glu3Lys) is associated with hyperlipidemia and cardiovascular diseases.
“Previous studies have reported that apoE5 (Glu3Lys) is associated with hyperlipidemia and cardiovascular diseases”
From Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys) (2018) · cites this paper as [3]
ApoE5 (Glu3Lys) has higher (twofold greater) LDL receptor-binding activity than normal apoE3.
“but this isoform has higher LDL receptor-binding activity than that of normal apoE3.”
From Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys) (2018) · cites this paper as [3]
APOE5 (Glu3Lys) is predominantly present in the Japanese population and has been shown to be associated with increased binding to the LDL receptor compared with apoE3.
“APOE5 (Glu3Lys) is predominantly present in the Japanese population14, 104) and has been shown to be associated with increased binding to the LDL receptor compared with apoE3 105).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [105]
Citations
Cites
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
Zannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
Zannis, V. I., Breslow, J. L., Utermann, G., Mahley, R. W., Weisgraber, K. H., Havel, R. J., Goldstein, J. L., Brown, M. S., Schonfeld, G., Hazzard, W. R., et al. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38094-9 · Cited by 436
Analysis of Apolipoprotein E5 Gene from a Patient with Hyperlipoproteinemia1
Tajima, S., Yamamura, T., & Yamamoto, A. (1988) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122420 · Cited by 42
Self-citation
Flagged first, then by citations
Research works printed but not linked: 21
- Mahley, 1983, Biochim. Biophys. Acta, 737, 192, 10.1016/0304-4157(83)90001-1 · DOI
- Weisgraber, 1981, J. Biol. Chem, 256, 9077, 10.1016/S0021-9258(19)52510-8 · DOI · Paper page
- Weisgraber, 1982, J. Biol. Chem, 257, 2518, 10.1016/S0021-9258(18)34954-8 · DOI · Paper page
- Utermann, 1977, Nature, 269, 604, 10.1038/269604a0 · DOI · Paper page
- Rall, 1982, 79, 4696
- Rall, 1983, J. Clin. Invest, 72, 1288, 10.1172/JCI111085 · DOI · Paper page
- Wardell, 1987, J. Clin. Invest, 80, 483, 10.1172/JCI113096 · DOI · Paper page
- Mahley, 1988, Science, 240, 622, 10.1126/science.3283935 · DOI · Paper page
- Yamamura, 1984, Atherosclerosis, 50, 159, 10.1016/0021-9150(84)90019-4 · DOI · Paper page
- Yamamura, 1984, J. Clin. Invest, 74, 1229, 10.1172/JCI111532 · DOI · Paper page
- Dong, 1990, Biochem. Biophys. Res. Commun, 168, 409, 10.1016/0006-291X(90)92336-X · DOI · Paper page
- Kunkel, 1985, 82, 488
- Urlaub, 1980, 77, 4216
- Mishina, 1984, Nature, 307, 604, 10.1038/307604a0 · DOI
- Chen, 1987, Mol. Cell. Biol, 7, 2745, 10.1128/MCB.7.8.2745 · DOI
- Tajima, 1989, J. Biochem, 105, 249, 10.1093/oxfordjournals.jbchem.a122648 · DOI · Paper page
- Fielding, 1979, J. Biol. Chem, 254, 8861, 10.1016/S0021-9258(19)86779-0 · DOI
- Innerarity, 1979, J. Biol. Chem, 254, 4186, 10.1016/S0021-9258(18)50713-4 · DOI · Paper page
- Wardell, 1991, J. Lipid Res, 32, 521, 10.1016/S0022-2275(20)42076-0 · DOI · Paper page
- Scahill, 1983, 80, 4654
- McCormick, 1984, Mol. Cell. Biol, 4, 166, 10.1128/MCB.4.1.166 · DOI
Cited by
Sorted by citations
Feussner, G., Scharnagl, H., Scherbaum, C., Acar, J., Dobmeyer, J., Lohrmann, J., Wieland, H., & März, W. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39106-9 · Cited by 21
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14
Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys)
Sasaki, M., Yasuno, T., Ito, K., Matsunaga, A., Hisano, S., Abe, Y., Miyake, K., Masutani, K., Nakashima, H., & Saito, T. (2018) · CEN Case Reports · doi:10.1007/s13730-018-0331-4 · Cited by 9
Metadata
- Authors
- Dong, L.-M., Yamamura, T., Tajima, S., & Yamamoto, A.
- Affiliations
- National Cerebral and Cardiovascular Center (JP)
- Institute for Protein Research, The University of Osaka (JP)
- ORCID
- Yamamoto, Akira
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 1992-09
- Volume
- 187
- Issue
- 2
- Pages
- 1180-1186
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2079237922
- Cited by
- 8
- References
- 4
- Citations by year
- 2025: 1 · 2021: 1 · 2018: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical and Biophysical Research Communications (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein E, apolipoprotein E3, LDL receptor, receptor binding, site-directed mutagenesis, hyperlipoproteinemia, atherosclerosis, sialic acid, sialylation, CHO cells
- MeSH terms
- Animals, Apolipoproteins E, Base Sequence, DNA, Electrophoresis, Polyacrylamide Gel, Fibroblasts, Cricetinae, Humans, Isoelectric Focusing, Molecular Sequence Data, Plasmids, Receptors, LDL, Tetrahydrofolate Dehydrogenase, Transfection, Gene Expression, Mutagenesis, Site-Directed, CHO Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
